Journal of Cardiovascular Disease Research
ISSN: 0975-3583,0976-2833 VOL 16, ISSUE 10, 2025

COMPARATIVE ANALYSIS OF REGULATORY REQUIREMENTS FOR FIXED DOSE COMBINATIONS (FDCs) IN INDIA, US AND EU

[1]Swamy Sekhar Gannabathula, [2] Raghava.D, 3 Nageswara Rao.K, 4 Naga Sravani.P

[1] PG Scholar, Department of Drug Regulatory Affairs, K.G.R.L College of Pharmacy, Bhimavaram, Andhra Pradesh, India,
[2] Principal and professor Department of Pharmaceutical Chemistry KGRL College of Pharmacy, Bhimvaram,West Godavari,Andhra Pradesh,India 534201,
3 Director and professor department of Pharmaceutical Analysis. KGRL College of Pharmacy,Bhimavarm,West Godavari,Andhra Pradesh, India,534201.
4 Assistant professor, Department of Drug Regulatory Affairs, K.G.R.L College of Pharmacy, Bhimavaram, Andhra Pradesh, India,

swamygannabathula333@gmail.com

Abstract
Fixed Dose Combinations (FDCs) have become an essential aspect of modern therapeutic strategies, particularly for chronic and infectious diseases. However, regulatory requirements for approval and marketing of FDCs vary significantly across regions. This project aims to perform a comprehensive comparative analysis of the regulatory frameworks governing FDCs in India, the United States (US), and the European Union (EU). The study will focus on classification, submission procedures, clinical data requirements, approval timelines, and post-marketing surveillance obligations. Understanding these differences is crucial for pharmaceutical companies seeking global registration of FDC products. The findings will offer regulatory professionals a concise roadmap for harmonizing regulatory submissions and ensuring compliance across markets.

Keywords: Fixed Dose Combinations (FDCs), Regulatory Requirements, Drug Approval Process, Clinical Data Requirements, Post-Marketing Surveillance, Regulatory Harmonization

Introduction
Fixed Dose Combinations (FDCs) have emerged as a pivotal component of modern pharmacotherapy, especially in the treatment of chronic and infectious diseases. An FDC is defined as a pharmaceutical product containing two or more active pharmaceutical ingredients (APIs) in a fixed ratio within a single dosage form. [1] The rationale behind FDCs is grounded in enhancing patient compliance, achieving synergistic therapeutic effects, and streamlining healthcare delivery—particularly in settings where access to medical supervision is limited or treatment regimens are complex.

Historically, the concept of combining therapeutic agents can be traced back to traditional medicine systems, where multiple herbs were used together to treat complex illnesses.[2] However, the scientific framework supporting FDCs gained traction in the mid-20th century with the emergence of diseases such as tuberculosis, malaria, and HIV/AIDS that required multi-drug regimens. These early applications demonstrated that simplified combination therapy could not only improve adherence but also significantly reduce the development of drug resistance. Endorsements by the World Health Organization (WHO) further cemented the role of FDCs in global public health programs. [3]

In contemporary medicine, FDCs are extensively used for managing chronic conditions like hypertension, diabetes, and dyslipidemia—areas where polypharmacy is common and long-term adherence is critical.[4] For example, the combination of metformin and glibenclamide improves glycemic control through complementary mechanisms, while antihypertensive FDCs like amlodipine and telmisartan optimize blood pressure regulation by targeting different physiological pathways.

Despite these clinical advantages, the development and approval of FDCs present unique challenges.[5] Ensuring chemical and pharmacokinetic compatibility among APIs, addressing concerns about fixed dosing, and evaluating the altered safety profiles of combinations all require rigorous scientific and regulatory scrutiny. Moreover, FDCs lack the flexibility of dose titration, which can be crucial in individualizing therapy.

The regulatory environment for FDCs is equally complex and varies widely across regions. In India, regulatory oversight has evolved in response to a surge in irrational FDCs, while the U.S. [6] FDA and the European Medicines Agency (EMA) have consistently followed stringent, evidence-based evaluation frameworks. This thesis explores these differences and aims to provide a comparative analysis of regulatory pathways in India, the US, and the EU.

The regulatory approval of Fixed Dose Combinations (FDCs) presents a complex landscape marked by both substantial challenges and notable opportunities. [7] Despite their therapeutic advantages—such as improved compliance, reduced pill burden, and synergistic effects—FDCs are subject to divergent regulatory interpretations and inconsistent classification criteria across jurisdictions.[8] This lack of global harmonization complicates development strategies, compelling sponsors to navigate varying requirements related to clinical data, dossier structure, and submission processes in each target market.

A key difficulty lies in the differing clinical evidence thresholds for approval. Some authorities, particularly in cases where the individual components are already well-established, accept bioequivalence or pharmacokinetic data alone. [9] Others demand full-scale clinical trials, even for previously approved molecules, thereby increasing cost and time to market. Designing robust trials for FDCs is inherently challenging, especially when attempting to demonstrate the added value of the combination over monotherapy, and to address potential drug-drug interactions or dose optimization complexities.

Regulatory timelines add another layer of uncertainty. In regions like India, while reforms have improved efficiency, approval durations may still be prolonged due to infrastructure gaps and multi-tiered review mechanisms. In contrast, agencies like the US FDA and the EMA offer more defined timelines, though their processes remain demanding in terms of data quality and regulatory rigor.

Nonetheless, promising opportunities are emerging. International harmonization efforts—such as those led by the International Council for Harmonisation (ICH)—aim to align technical standards and reduce redundancy in submissions.[10] Advances in real-world evidence (RWE), adaptive trial designs, and digital tools for pharmacovigilance also offer pathways to streamline both pre- and post-marketing evaluation. [11]

Furthermore, patient-focused approaches, including the use of adherence data and patient-reported outcomes, are gaining traction in regulatory decision-making. These trends suggest a shift toward more holistic benefit-risk assessments. [12]

To fully realize these opportunities, collaborative engagement among industry stakeholders, regulatory authorities, and healthcare providers is essential. [] A coordinated global approach, coupled with regulatory innovation, is key to ensuring timely access to safe, effective, and rational FDCs worldwide.

Methodology

This study employs a qualitative comparative analysis (QCA) approach to examine the regulatory frameworks governing Fixed Dose Combinations (FDCs) in India, the United States, and the European Union. The goal is to identify both commonalities and distinctions in how each jurisdiction classifies, approves, and monitors FDCs, providing a comprehensive understanding of their regulatory landscapes.

QCA is particularly suitable for analyzing the complex and often nuanced regulatory environments that govern pharmaceutical approvals. Rather than relying on quantitative metrics, this method emphasizes thematic patterns, context-specific interpretations, and regulatory intent. It allows the integration of diverse data sources, including regulatory guidelines, enforcement actions, and case-specific developments, offering a holistic view of FDC regulation.

The analysis draws from primary sources such as official documents published by CDSCO (India), USFDA (United States), and EMA (European Union), along with international guidance from organizations like the WHO and ICH. These include policy manuals, clinical trial requirements, marketing authorization procedures, and pharmacovigilance protocols. Peer-reviewed literature and regulatory case studies serve as secondary sources, offering context and critical evaluation of these frameworks.

Data were organized by region and further categorized into key regulatory themes—classification criteria, approval pathways, clinical data requirements, timelines, and post-marketing surveillance. A tabular format was employed to enable side-by-side comparisons across regions, making it easier to identify areas of convergence and divergence.

To support deeper understanding, flowcharts were created to visualize regulatory processes such as submission pathways and pharmacovigilance mechanisms. These diagrams helped map procedural differences and highlighted regulatory efficiency or complexity in each jurisdiction. Additionally, qualitative content analysis techniques, including thematic coding, were applied to extract policy rationales and underlying regulatory philosophies from textual data. This interpretative step added depth to the procedural analysis, uncovering strategic priorities unique to each regulatory body.

An iterative review process was also adopted—emerging insights from preliminary comparisons informed subsequent rounds of data collection and categorization. This cyclical method improved analytical precision and ensured that the conclusions remained grounded in real-world regulatory practice.

Overall, this methodology provided both structural clarity and contextual richness, enabling a nuanced comparative analysis that captures the complexity and strategic implications of FDC regulation in the three selected regions.

Results

This section presents the core comparative findings derived from the qualitative analysis of regulatory frameworks for Fixed Dose Combinations (FDCs) across India, the United States, and the European Union. The results are organized into key thematic areas to facilitate clarity: classification of FDCs, approval process workflows, timeline and cost considerations, and post-marketing obligations. Each subsection is supported by tabular data, flowcharts, and graphical illustrations where appropriate, enabling both visual and descriptive comprehension of similarities and distinctions between regions.

Classification of Fixed Dose Combinations

The classification of FDCs forms the foundational step in the regulatory review and approval process, as it dictates the applicable regulatory pathways, data requirements, and safety assessments. Table 1 summarizes the regulatory classification criteria employed by each jurisdiction, highlighting the basis for categorization, associated risk stratifications, and specific subtypes recognized within the FDC framework.

Table 1: Classification of FDCs

S.NO	Classification Aspect	India (CDSCO)	United States (USFDA)	European Union (EMA)
1	Definition of FDC	Combination of two or more active drugs in a fixed ratio for single dosage form	Combination products defined as therapeutic combinations, drug-device, or biologic combinations	Combination medicinal products composed of two or more active substances in a single dosage
2	Categories	New FDCs (requiring full clinical data), Modified FDCs, Already approved combinations	Single-entity drugs, co-packaged, and fixed combinations; regulated based on primary mode of action	Co-formulated, co-packaged, and fixed combinations with risk-based classification
3	Risk-based stratification	High-risk (new combinations, novel ratios), Low-risk (existing combinations)	Based on complexity, novelty, and safety profile	Categorized by complexity and regulatory pathway required (centralized vs decentralized)
4	Regulatory pathways	Full NDA for new FDCs, abbreviated for modifications or established combos	NDA, ANDA, 505(b)(2) depending on approval type and data	Centralized, decentralized, mutual recognition procedures
5	Clinical data requirements	Full clinical trials often required for new combos	Depends on submission type; sometimes bioequivalence studies suffice	Clinical trials may be required based on product classification and risk

6	Post-approval monitoring	Mandatory pharmacovigilance and periodic safety update reports	REMS and FDA safety programs	Risk Management Plans and periodic safety reports

The Indian regulatory framework categorizes FDCs primarily by novelty and risk, necessitating comprehensive clinical data for newly introduced combinations or those involving significant changes. The USFDA employs a broader definition encompassing combination drugs and products integrating devices or biologics, with regulatory pathways determined by the nature of the product and prior approvals. The EMA distinguishes between co-formulated and co-packaged products, applying risk-based classifications to direct the approval process via centralized or decentralized routes.

This classification variability underscores the importance of strategic regulatory planning for global FDC developers. While India's approach emphasizes stringent evaluation for new combinations, the US and EU provide more nuanced pathways, allowing for abbreviated or alternative submission routes depending on product complexity and existing data. Understanding these distinctions is essential for optimizing development timelines and resource allocation.

Approval Process Flowchart Comparison

The regulatory approval process for Fixed Dose Combinations (FDCs) differs significantly across India, the United States, and the European Union. These differences reflect each region's legal framework, regulatory philosophy, and operational mechanisms. Table 2 outlines the stepwise approval workflows, highlighting submission requirements, evaluation stages, and decision-making authorities.

Table 2: Approval process flowchart comparison

Step	India (CDSCO)	United States (USFDA)	European Union (EMA)
Pre-submission Consultation	Optional meetings with CDSCO for complex FDCs	Pre-IND meeting available for guidance	Scientific advice meetings with EMA or national agencies
Submission Type	New Drug Application (NDA) for new FDCs; Simplified applications for modifications	NDA (505(b)(1)), ANDA (505(j)) or 505(b)(2) for hybrids	Centralized Marketing Authorization Application (MAA), Decentralized Procedure (DCP), Mutual Recognition Procedure (MRP)

Initial Screening	Completeness check by CDSCO	Filing review by FDA	Validation by EMA or national competent authority
Technical Review	Clinical, quality, and safety evaluation by expert committees	Scientific review divisions (clinical, chemistry, pharmacology)	CHMP evaluation with input from rapporteur and co-rapporteur
Inspection and Audit	Site inspections for manufacturing and clinical sites	Good Manufacturing Practice (GMP) inspections	GMP inspections coordinated by EMA or national authorities
Advisory Committee Review	Expert panel review may be convened	Advisory committee meetings for novel or high-risk products	EMA expert committees for scientific evaluation
Approval Decision	CDSCO issues marketing approval	FDA issues approval letter or Complete Response Letter	European Commission grants marketing authorization
Post-approval Obligations	Pharmacovigilance, annual reports	REMS, post-marketing commitments	Risk Management Plans (RMPs), PSUR submissions

Timeline and Cost Comparison

Approval timelines and associated fees are critical factors influencing the development and commercialization strategies for Fixed Dose Combinations (FDCs). Table 3 summarizes the average review durations, official regulatory timelines, and fee structures in India, the United States, and the European Union, providing insight into the operational efficiency and financial implications in each region.

Table 3: Regulatory Timelines and Fees for FDC Approvals in India, US, and EU

Aspect	India (CDSCO)	United States (USFDA)	European Union (EMA)
Official Review Timeline	Typically 12-18 months for new FDCs	Standard review ~10 months; priority review ~6 months	Centralized: 210 days (excluding clock stops); Decentralized/MRP varies

Average Actual Approval Time	14-24 months depending on complexity and backlog	Approximately 8-14 months	Approximately 8-12 months
Application Fees	Moderate; varies by application type (~INR 10,000 - 2,00,000)	Higher; ranges from $1,000 to over $3 million for NDA	Varies; centralized procedure fees around €300,000
Additional Fees	Inspection fees, post-approval variation fees	User fees, advisory committee fees	Fees for scientific advice, inspection, and variations
Fast-Track or Accelerated Approval	Limited formal provisions; some priority reviews for critical drugs	Accelerated approval, breakthrough therapy designation	Conditional marketing authorization and accelerated assessment
Fee Waivers/Reductions	Available for startups, small enterprises	Limited; some reductions for small businesses	Some fee reductions for SMEs and orphan medicines

In India, the review process for FDCs is generally lengthier, impacted by resource constraints and increasing application volumes. Official timelines for new drug applications range between 12 to 18 months, but actual approval can extend up to 24 months for complex submissions or those requiring additional data. The application fees are relatively moderate, making the process more accessible to domestic manufacturers and small companies.

The United States offers a more expedited review system, particularly through priority and accelerated programs aimed at addressing unmet medical needs. Standard review times average around 10 months, though priority designations can shorten this to approximately six months. The user fees imposed by the FDA are among the highest globally, reflecting the extensive scientific evaluation and regulatory infrastructure involved.

The European Union follows a rigorous but streamlined process under the centralized procedure with a fixed review timeline of 210 days excluding applicant response times (clock stops). This timeline supports simultaneous approval across member states. Fees in the EU tend to be substantial, with the centralized procedure costing hundreds of thousands of euros, reflecting the high regulatory standards and coordination efforts.
Fast-track and accelerated approval mechanisms exist in all regions but differ in scope and utilization. India's provisions are more limited compared to the US FDA's breakthrough therapy designation or the EU's conditional marketing authorizations. Fee waivers and reductions are available selectively, with India and the EU providing support to small and medium-sized enterprises to encourage innovation.

The comparative analysis of timelines and costs reveals a trade-off between speed, regulatory rigor, and financial burden. Pharmaceutical companies must weigh these factors carefully when strategizing global development and marketing of FDCs, considering the potential impact on market access and return on investment.

Post-Marketing Obligations Comparison

Post-marketing surveillance is a critical phase in the lifecycle of Fixed Dose Combinations (FDCs), ensuring ongoing safety, efficacy, and risk management after product approval. Table 4 presents a comparative overview of the pharmacovigilance systems, reporting requirements, and regulatory expectations in India, the United States, and the European Union.

Table 4: Post-Marketing Obligations Comparison

Aspect	India (CDSCO)	United States (USFDA)	European Union (EMA)
Pharmacovigilance Program	Pharmacovigilance Programme of India (PvPI)	FDA Adverse Event Reporting System (FAERS)	EudraVigilance
Periodic Safety Reporting	Periodic Safety Update Reports (PSURs)	Periodic Adverse Drug Experience Reports (PADERs)	Periodic Safety Update Reports (PSURs)
Risk Management Plans (RMP)	Not mandatory but recommended for new drugs	Required for drugs with safety concerns	Mandatory RMPs with detailed risk minimization measures
Post-Marketing Commitments	Clinical trial follow-ups, observational studies	Post-marketing requirements, Risk Evaluation and Mitigation Strategies (REMS)	Post-authorization safety studies and additional data requests
Adverse Event Reporting	Mandatory reporting by marketing authorization holders, health professionals encouraged	Mandatory for manufacturers, voluntary for healthcare providers	Mandatory for marketing authorization holders and healthcare professionals
Signal Detection and Analysis	Conducted by CDSCO and PvPI using collected reports	Continuous signal detection via FAERS database	Continuous pharmacovigilance through EudraVigilance database
Public Access and Transparency	Limited public disclosure of pharmacovigilance data	Publicly accessible FDA safety alerts and databases	Regular updates and public access via EMA website

Graphical Representation of Key Findings

Visual representation of comparative data provides clearer insight into the regulatory landscapes governing Fixed Dose Combinations (FDCs). Two critical parameters — average

approval timelines and frequency of regulatory updates — are illustrated through graphs to highlight differences and trends in India, the United States, and the European Union.

Average Approval Timelines

A bar graph depicting the average approval times for FDCs across the three regions clearly demonstrates variation in regulatory efficiency and procedural complexity. The vertical axis represents the duration in months, while the horizontal axis shows the regions — India, US, and EU.

- The graph reveals that India has the longest average approval period, ranging approximately between 14 to 24 months depending on the nature of the FDC and backlog in review.
- The US exhibits a relatively shorter and more consistent approval timeline, with averages from 8 to 14 months, influenced by standard and priority review pathways.
- The EU shows a more streamlined process, with centralized procedures generally completing within 8 to 12 months, reflecting harmonized review timelines across member states.

This visualization emphasizes the practical implications of regulatory timelines on pharmaceutical development strategies, where faster approvals may accelerate market access and revenue generation.

Figure 1: Average Approval Timelines for FDCs in India, US, and EU



Frequency of Regulatory Updates

A line graph or histogram compares the frequency of regulatory guideline updates and notifications related to FDCs over a defined period (e.g., last 10 years) in the three regions.

- India demonstrates periodic updates often triggered by emerging safety concerns, policy reforms, or industry consultations, reflecting evolving regulatory maturity.
- The US shows a higher frequency of updates, driven by rapid scientific advancements, pharmacovigilance findings, and initiatives to streamline drug development.

- The EU's update frequency is moderate but consistent, driven by continuous harmonization efforts within the EU regulatory framework and adaptation to international guidelines.

Such graphical data underscores the dynamic nature of regulatory environments and highlights the importance of ongoing monitoring by pharmaceutical companies to remain compliant.

Together, these graphs offer a snapshot of regulatory performance and responsiveness, guiding stakeholders in planning submission strategies and post-approval compliance for FDCs in multiple jurisdictions.

Figure 2: Frequency of Regulatory Updates for FDCs Over the Last Decade



Discussion

Interpretation of Results with Strategic Implications

The comparative analysis of regulatory frameworks for Fixed Dose Combinations (FDCs) across India, the United States, and the European Union reveals significant variation in how each region approaches classification, approval, and post-marketing obligations. India's framework, while improving, still exhibits procedural delays, resource limitations, and inconsistent implementation. In contrast, the US and EU systems offer structured, transparent, and time-bound processes, albeit with higher operational and financial demands.

These differences have direct implications for pharmaceutical companies aiming for multi-regional product launches. The need to adapt to jurisdiction-specific requirements, ranging from dossier structures to clinical trial data expectations, translates into increased costs and extended development timelines. Companies must strategically evaluate where and how to initiate regulatory submissions, balancing the promise of faster access in developed markets with the growth potential in emerging economies like India.

Regulatory Stringency and Transparency

The level of regulatory stringency reflects each region's commitment to patient safety, public health priorities, and institutional capacity. The US and EU are marked by high regulatory rigor, requiring detailed clinical trial evidence, formal risk management plans, and

comprehensive post-marketing surveillance. India has historically employed a more flexible system, shaped by the need to ensure affordability and accessibility. However, recent reforms such as the NDCT Rules 2019 demonstrate a shift toward increased scrutiny and formalization. Transparency plays a crucial role in regulatory accountability and industry trust. The US stands out for its publicly accessible databases, safety alerts, and decision summaries, which aid both compliance and public confidence. The EU also maintains consistent disclosure through EMA's portal. In India, while CDSCO has improved public communication, access to regulatory rationales and safety updates remains limited, potentially undermining stakeholder engagement and preparedness.

Gaps and Redundancies in the Regulatory Landscape

The lack of harmonization among the three regulatory systems generates inefficiencies that can hinder timely market access. Diverging definitions, risk stratification methods, and submission formats lead to redundancy in data generation and administrative duplication. For example, while India may accept bioequivalence data for certain FDCs, the US and EU often demand comprehensive clinical trial results. This lack of alignment forces companies to conduct multiple studies or repackage the same data differently for each region.

Post-marketing obligations also differ substantially. The varying formats and frequencies of safety reporting—PADERs in the US, PSURs in the EU and India—create a fragmented system that complicates global pharmacovigilance operations. Moreover, overlapping roles between CDSCO and state-level authorities in India can lead to inconsistent interpretations and procedural delays.

Challenges Faced by Global Pharmaceutical Companies

Pharmaceutical manufacturers, especially those targeting multiple markets, must invest in extensive regulatory expertise and infrastructure. The differing timelines and levels of rigor not only impact product launch strategies but also affect lifecycle management and cost-effectiveness. While larger multinational companies may be equipped to navigate these hurdles, smaller firms may find the complexity prohibitive, limiting innovation and competition.

Regulatory unpredictability in some regions further deters investment and long-term planning. In contrast, the reliability of processes in the US and EU supports faster decision-making, despite higher regulatory costs. These challenges highlight the need for risk-adjusted market entry strategies and close coordination between regulatory, clinical, and commercial teams.

The Case for Global Harmonization

There is a growing need for convergence among global regulatory frameworks, especially for products like FDCs that are vital to managing chronic and multi-drug therapies. Harmonizing key aspects—such as clinical trial protocols, dossier templates, and safety reporting mechanisms—can reduce duplication and support parallel submissions across jurisdictions.
International frameworks like those developed by the International Council for Harmonisation (ICH) and the World Health Organization (WHO) provide a foundation for greater alignment. Regulatory collaboration through mutual recognition agreements or joint reviews could help streamline approvals, minimize delays, and promote more equitable access to critical therapies worldwide.

Impact on Innovation and Access

Ultimately, regulatory frameworks directly influence innovation and patient access. While stringent oversight ensures therapeutic safety and efficacy, overly burdensome systems can delay product development and increase costs. On the other hand, lenient yet inconsistent regulations may compromise safety and undermine public trust.

Striking a balance between regulatory rigor and operational efficiency is key. A harmonized and predictable regulatory environment would not only support faster access to innovative FDCs but also encourage investment in underserved therapeutic areas. Improved coordination across agencies would enhance global health outcomes, especially in regions grappling with complex disease burdens and limited treatment options.

Conclusion

This comparative analysis of regulatory frameworks governing Fixed Dose Combinations (FDCs) across India, the United States, and the European Union reveals both convergence in regulatory goals and divergence in implementation. While all three regions strive to ensure the safety, efficacy, and quality of FDCs, they differ significantly in terms of classification methods, approval processes, clinical data requirements, and post-marketing surveillance systems.

India's regulatory system is evolving, driven by reforms such as the NDCT Rules (2019), but still faces challenges in terms of consistency and transparency. In contrast, the US FDA and EMA operate under more structured and transparent systems that support predictable timelines and advanced regulatory tools such as REMS and centralized approvals. These differences influence pharmaceutical companies' development strategies, requiring tailored approaches to navigate region-specific expectations and optimize global market entry.

The need for regulatory convergence is increasingly evident as FDCs become central to treating chronic and complex diseases. International harmonization—through standardization of clinical protocols, adoption of the Common Technical Document (CTD), and alignment of post-marketing requirements—can reduce redundancy and expedite access to medicines. Collaboration via mutual recognition agreements and shared regulatory reviews offers a practical pathway toward greater efficiency without compromising safety.

To support this evolution, policymakers must foster inter-agency collaboration, invest in digital infrastructure, and engage with stakeholders, while pharmaceutical professionals must proactively align development and pharmacovigilance strategies with the expectations of each regulatory body. Continued research on the economic, clinical, and operational impacts of regulatory divergence will further support global efforts to harmonize FDC regulation and improve patient outcomes worldwide.

References

1. Graham, S. M., Grzemska, M., & Gie, R. P. (2015). The background and rationale for a new fixed-dose combination for first-line treatment of tuberculosis in children. *The International Journal of Tuberculosis and Lung Disease*, *19*(12), S3-S8.

2. Bangalore, S., Kamalakkannan, G., Parkar, S., & Messerli, F. H. (2007). Fixed-dose combinations improve medication compliance: a meta-analysis. *The American journal of medicine*, *120*(8), 713-719.
3. Keith, J. A., Verdeli, H., & Vousoura, E. (2011). Evaluating the clinical significance of depression treatment: Implications for global mental health research. *International Journal of Mental Health*, *40*(3), 3-28.
4. Iwama, M. (2007). Culture and occupational therapy: meeting the challenge of relevance in a global world. *Occupational Therapy International*, *14*(4).
5. McGettigan, P., Roderick, P., Mahajan, R., Kadam, A., & Pollock, A. M. (2015). Use of fixed dose combination (FDC) drugs in India: central regulatory approval and sales of FDCs containing non-steroidal anti-inflammatory drugs (NSAIDs), metformin, or psychotropic drugs. *PLoS medicine*, *12*(5), e1001826.
6. Desai, D., Wang, J., Wen, H., Li, X., & Timmins, P. (2013). Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms. *Pharmaceutical development and technology*, *18*(6), 1265-1276.
7. Sharma, A., Khante, S., Mahadik, K. R., & Gaikwad, V. L. (2020). Regulatory perspective of international agencies for development of biosimilar products (monoclonal antibodies): An overview. *Therapeutic Innovation & Regulatory Science*, *54*, 965-977.
8. Konwar, M., Maurya, M. R., Nishandar, T. B., Thatte, U. M., & Gogtay, N. J. (2021). An evaluation of drug lag for new drugs approved by the Indian regulator relative to the United States, European Union, and Japanese regulatory agencies: a 15-year analysis (2004–2018). *Perspectives in Clinical Research*, *12*(3), 159-164.
9. Yuri Gasparyan, A., Stavropoulos-Kalinoglou, A., P Mikhailidis, D., E Toms, T., MJ Douglas, K., & D Kitas, G. (2010). The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. *Current vascular pharmacology*, *8*(4), 437-449.
10. Maron, D. J., Hochman, J. S., O'Brien, S. M., Reynolds, H. R., Boden, W. E., Stone, G. W., ... & ISCHEMIA Trial Research Group. (2018). International study of comparative health effectiveness with medical and invasive approaches (ISCHEMIA) trial: rationale and design. *American heart journal*, *201*, 124-135.
11. van Nierop, K., & de Groot, C. (2002, August). Human follicular dendritic cells: function, origin and development. In *Seminars in immunology* (Vol. 14, No. 4, pp. 251-257). Academic Press.
12. Tharme, R. E. (2003). A global perspective on environmental flow assessment: emerging trends in the development and application of environmental flow methodologies for rivers. *River research and applications*, *19*(5-6), 397-441.
13. DiPette, D. J., Skeete, J., Ridley, E., Campbell, N. R., Lopez-Jaramillo, P., Kishore, S. P., ... & Ordunez, P. (2018). Fixed-dose combination pharmacologic therapy to improve hypertension control worldwide: clinical perspective and policy implications. *The Journal of Clinical Hypertension*, *21*(1), 4.
14. Sawicki-Wrzas et al. Fixed dose combination approval: regulatory considerations in US, Europe, India. *Res J Pharm Technol*. 2021;14(2):87–94.
15. Balasubramanian D, et al. Retrospective evaluation of FDC approvals in India. *Int J Pharm Chem Res*. 2014;3(3):402–14.
16. Suthakaran R. Regulatory requirements for FDCs: ASEAN, GCC & USFDA compared. *J Pharm Res*. 2014;8(1):59–63.
17. Pateriya S, Janodia MD, Deshpande PB, et al. Regulatory aspects of FDC exports in GCC. *J Young Pharm*. 2011;3(2):155–62.

18. Al-Essa R, Salek SS, Walker SR. Regulatory review practices for FDCs in GCC. *Drug Inf J*. 2012;46(1):57–64.
19. Mohit A, Deep A, Khurana G, Kumar J, Monga A. Comparison of FDC regulatory models: ASEAN vs. GCC. *Appl Clin Res Regul Aff*. 2019;6(1):62–70.
20. Abouchacra S, Obaidli A, Al-Ghamdi SM, et al. FDCs in essential medicines lists: GCC analysis. *Saudi J Kidney Dis Transpl*. 2016;27 Suppl 1:51–61.
21. Weber AS, Turjoman R, Shaheen Y, et al. E-health and digital dossier submission in GCC. *J Telemed Telecare*. 2017;23(4):452–9.
22. Apratim PM, Basarkar GD. Comparative overview of generic and FDC regulation: US, Europe, India. *Int J Drug Regul Affairs*. 2025;13(1):40–48.
23. Parth R, Patel K, Patel K, Gupta M, Bodhe S. Fixed dose combination approval in USA, India, Australia: A comparative study. *Int J Pharm Pharm Res*. 2025;31(1):1–9.
24. Raval P, et al. Generic and FDC regulatory timelines: India vs. US & EU experience. *IJPPR*. 2025;31(1):1–8.
25. Hornor R. Generic and combination product regulation: US landscape. *US Pharmacist*. 2009;34(12):240–7.
26. Koornneef E, Robben P, Hajat C, Ali A. Regulatory guideline development for combination products in GCC. *J Eval Clin Pract*. 2015;21(6):1006–13.
27. Lambert G. Delays in FDC approval in the Middle East: resolution strategies. CMR Int; 2000.
28. Centre for Innovation in Regulatory Science. FDCs and new drug approvals in ICH countries 2010–2020. London: CIRS; 2021.
29. Mallia-Milanes A. Evaluation of regulatory review process for FDCs: PhD thesis. Cardiff University; 2006.
30. Badjatya JK, Jangid A, Dodiya P, et al. Regulatory requirements for FDC registration in emerging markets. *Int J Drug Reg Affairs*. 2022;10(1):51–82.